(Q39957550)

15 September 2017

Extracellular DNA and F-actin as targets in antibiofilm cystic fibrosis therapy (English)

1 reference

15 September 2017

0 references

1

1 reference

15 September 2017

2

Niels Høiby

0 references

publication date

1 August 2009

1 reference

15 September 2017

3

1 reference

based on heuristic

inferred from page(s)

published in

Future Microbiology

1 reference

15 September 2017

4

1 reference

15 September 2017

6

1 reference

15 September 2017

645-647

1 reference

Neutrophil enhancement of Pseudomonas aeruginosa biofilm development: human F-actin and DNA as targets for therapy

15 September 2017

1 reference

Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophils

21 January 2018

1 reference

Anionic poly(amino acid)s dissolve F-actin and DNA bundles, enhance DNase activity, and reduce the viscosity of cystic fibrosis sputum.

21 January 2018

1 reference

Extracellular DNA Required for Bacterial Biofilm Formation

21 January 2018

1 reference

A characterization of DNA release in Pseudomonas aeruginosa cultures and biofilms

21 January 2018

1 reference

Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients.

21 January 2018

1 reference

Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice

21 January 2018

1 reference

Early rise of anti-pseudomonas antibodies and a mucoid phenotype of pseudomonas aeruginosa are risk factors for development of chronic lung infection--a case control study.

21 January 2018

1 reference

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FMB.09.38

1 reference

15 September 2017

1 reference

PubMed ID

19659420